| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
|
Nat Med
|
2005
|
1.69
|
|
2
|
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
|
Blood
|
2012
|
1.63
|
|
3
|
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
|
Blood
|
2010
|
1.53
|
|
4
|
CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
|
Clin Cancer Res
|
2007
|
1.51
|
|
5
|
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.
|
Proc Natl Acad Sci U S A
|
2006
|
1.50
|
|
6
|
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
|
Clin Cancer Res
|
2005
|
1.49
|
|
7
|
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
|
J Clin Oncol
|
2005
|
1.45
|
|
8
|
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
|
Blood
|
2004
|
1.41
|
|
9
|
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
|
Blood
|
2008
|
1.30
|
|
10
|
CD74 is expressed by multiple myeloma and is a promising target for therapy.
|
Clin Cancer Res
|
2004
|
1.25
|
|
11
|
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
|
Clin Cancer Res
|
2005
|
1.22
|
|
12
|
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
|
Cancer Res
|
2008
|
1.15
|
|
13
|
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
|
Cancer Res
|
2008
|
1.08
|
|
14
|
Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.
|
J Med Chem
|
2008
|
1.01
|
|
15
|
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
|
Blood
|
2009
|
0.99
|
|
16
|
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
|
Blood
|
2009
|
0.96
|
|
17
|
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
|
Mol Cancer Ther
|
2013
|
0.96
|
|
18
|
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
|
Blood
|
2007
|
0.93
|
|
19
|
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
|
Clin Cancer Res
|
2003
|
0.92
|
|
20
|
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
|
Int J Cancer
|
2004
|
0.90
|
|
21
|
Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
|
Clin Cancer Res
|
2006
|
0.89
|
|
22
|
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
|
Clin Cancer Res
|
2009
|
0.89
|
|
23
|
A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.
|
J Nucl Med
|
2012
|
0.89
|
|
24
|
Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
|
Clin Cancer Res
|
2005
|
0.87
|
|
25
|
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.
|
Bioconjug Chem
|
2012
|
0.85
|
|
26
|
Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells.
|
Mol Cancer Ther
|
2010
|
0.85
|
|
27
|
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.
|
PLoS One
|
2013
|
0.85
|
|
28
|
Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.
|
Blood
|
2011
|
0.84
|
|
29
|
A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.
|
PLoS One
|
2012
|
0.83
|
|
30
|
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
|
Mol Cancer Ther
|
2011
|
0.82
|
|
31
|
Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines.
|
PLoS One
|
2012
|
0.81
|
|
32
|
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
|
Biol Blood Marrow Transplant
|
2012
|
0.80
|
|
33
|
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer.
|
Cancer Res
|
2004
|
0.79
|
|
34
|
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
|
Mol Cancer
|
2014
|
0.78
|
|
35
|
A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.
|
Bioconjug Chem
|
2009
|
0.78
|
|
36
|
Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16).
|
Int J Oncol
|
2005
|
0.75
|